Victory Capital Management Inc. Trims Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Victory Capital Management Inc. decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,680 shares of the biopharmaceutical company’s stock after selling 724 shares during the period. Victory Capital Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $9,399,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. grew its position in Alnylam Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company’s stock worth $1,792,542,000 after acquiring an additional 50,366 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Alnylam Pharmaceuticals by 5.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock worth $550,837,000 after acquiring an additional 201,784 shares in the last quarter. Capital International Investors increased its stake in Alnylam Pharmaceuticals by 1.8% during the 1st quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock worth $545,674,000 after buying an additional 64,560 shares during the period. Capital Research Global Investors boosted its holdings in Alnylam Pharmaceuticals by 7.3% in the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after purchasing an additional 214,908 shares during the period. Finally, Norges Bank acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth $390,438,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $20,563,480. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CMO Pushkal Garg sold 2,103 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $485,771.97. Following the completion of the transaction, the chief marketing officer now directly owns 15,609 shares of the company’s stock, valued at approximately $3,605,522.91. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the sale, the chief executive officer now owns 73,441 shares in the company, valued at $20,563,480. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 103,148 shares of company stock valued at $25,658,824. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $265.27 on Friday. The company has a market capitalization of $34.06 billion, a P/E ratio of -98.98 and a beta of 0.38. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $287.55. The company’s fifty day moving average is $258.53 and its two-hundred day moving average is $194.81.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to analysts’ expectations of $447.22 million. The business’s quarterly revenue was up 107.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.21) EPS. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ALNY. HC Wainwright reiterated a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, August 30th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $220.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, September 9th. Raymond James boosted their price target on shares of Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 4th. Finally, Canaccord Genuity Group boosted their target price on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Seven analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $279.14.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.